Engineering BCMA-CAR T cells to overcome CD19-negative relapse in B cell non-Hodgkin lymphomas

被引：0
|
作者：
Antonana-Vildosola, A. [1 ]
Perez-Amill, L. [1 ]
Sune, G. [1 ]
Castella, M. [1 ]
Najjar, A. [2 ]
Urbano, A. [1 ,3 ]
Martin-Antonio, B. [1 ,3 ]
机构：
[1] IDIBAPS, Barcelona, Spain
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Josep Carreras Leukemia Res Inst, Barcelona, Spain
来源：
HUMAN GENE THERAPY | 2019年 / 30卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P164
引用
收藏
页码：A67 / A68
页数：2
相关论文
共 50 条
  • [21] Targeting CD19-Negative Relapsed B-Acute Lymphoblastic Leukemia Using Trivalent CAR T Cells
    Fousek, Kristen
    Watanabe, Junji
    George, Ann
    Byrd, Tiara
    An, Xingyue
    Samaha, Hebatalla
    Salsman, Vita
    Navai, Shoba
    Jang, Albert
    Kim, Hye Na
    Joseph, Sujith
    Baker, Matthew
    Varadarajan, Navin
    Hegde, Meenakshi
    Kim, Yong-Mi
    Heisterkamp, Nora
    Abdel-Azim, Hisham
    Ahmed, Nabil
    MOLECULAR THERAPY, 2018, 26 (05) : 298 - 298
  • [22] Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
    Younes, Sheren
    Libert, Diane
    Zhao, Shuchun
    Johnsrud, Andrew
    Bharadwaj, Sushma
    Majzner, Robbie
    Frank, Matthew
    Miklos, David
    Natkunam, Yasodha
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1046 - 1048
  • [23] CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
    Onea, Alexandra S.
    Jazirehi, Ali R.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (02): : 403 - 424
  • [24] Detection of Aberrant CD58 Expression in a Wide Spectrum of Hodgkin and Non-Hodgkin Lymphomas: Implications for CAR T Cell Resistance
    Younes, Sheren
    Libert, Diane
    Zhao, Shuchun
    Johnsrud, Andrew
    Bharadwaj, Sushma
    Majzner, Robbie
    Frank, Matthew
    Miklos, David
    Natkunam, Yasodha
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1046 - 1048
  • [25] A Novel CD19-Anti-CD20 Bridging Protein Prevents and Reverses CD19-Negative Relapse from CAR19 T Cell Treatment In Vivo
    Rennert, Paul
    Su, Lihe
    Dufort, Fay
    Birt, Alyssa
    Sanford, Tom
    Wu, Lan
    Ambrose, Christine
    Lobb, Roy
    BLOOD, 2019, 134
  • [26] Targeting Primary Pre-B Cell Acute Lymphoblastic Leukemia and CD19-Negative Relapses Using Trivalent CAR T Cells
    Fousek, Kristen
    Watanabe, Junji
    George, Ann
    An, Xingyue
    Samaha, Hebatalla
    Navai, Shoba Alaska
    Byrd, Tiara T.
    Jang, Albert
    Kim, Hye Na
    Joseph, Sujith
    Baker, Matthew
    Varadarajan, Navin
    Hegde, Meenakshi G.
    Kim, Yong-Mi
    Heisterkamp, Nora
    Abdel-Azim, Hisham
    Ahmed, Nabil
    BLOOD, 2017, 130
  • [27] Upregulation of CD19 by low-dose chidamide promotes CAR T cells functionality in B-cell non-Hodgkin lymphoma
    Ni, Ying
    Zhang, Qun
    Tang, Xiaochen
    Li, Xiuchun
    Ye, Shiguang
    Lu, Yan
    Liang, Aibin
    Li, Ping
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [28] Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.
    Fousek, Kristen
    Watanabe, Junji
    George, Ann
    An, Xingyue
    Samaha, Heba Samir
    Navai, Shoba Alaska
    Byrd, Tiara T.
    Jang, Albert
    Kim, Hye Na
    Joseph, Sujith
    Baker, Matthew
    Varadarajan, Navin
    Hegde, Meenakshi G.
    Kim, Yong-Mi
    Heisterkamp, Nora
    Abdel-Azim, Hisham M.
    Ahmed, Nabil M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [29] Prognostic comparison of B and T cell non-Hodgkin's lymphomas.
    Kim, HS
    Koh, JH
    Park, KW
    Choi, JH
    Nam, DK
    Hyun, BH
    Kim, HC
    BLOOD, 1997, 90 (10) : 3913 - 3913
  • [30] Cytotoxic T lymphocyte recognition of non-hodgkin's B cell lymphomas
    Krensky, AM
    IMMUNOLOGIC RESEARCH, 1996, 15 (02) : 91 - 97
12345